(Q38526988)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

review article

1 reference

title

Human recombinant lysosomal enzymes produced in microorganisms (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author

Carlos J Alméciga-Díaz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Raúl A Poutou-Piñales

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Ángela J Espejo-Mojica

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Alexander Rodríguez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Ángela Mosquera

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Dennis Díaz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Laura Beltrán

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sergio Díaz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Natalia Pimentel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Jefferson Moreno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Jhonnathan Sánchez

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Oscar F Sánchez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Henry Córdoba

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Luis A Barrera

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

6 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

13-23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26071627%20AND%20SRC:MED&resulttype=core&format=json

Treating lysosomal storage disorders: current practice and future prospects

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme replacement therapy for lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Recombinant therapeutic protein production in cultivated mammalian cells: current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Human cells: new platform for recombinant therapeutic protein production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression of recombinant human GM2-activator protein in insect cells: purification and characterization by mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production of recombinant proteins by microbes and higher organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Protein aggregation and bioprocessing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Solubilization and refolding of bacterial inclusion body proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Protein aggregation in recombinant bacteria: biological role of inclusion bodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Manufacturing of recombinant therapeutic proteins in microbial systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Bacterial expression systems for recombinant protein production: E. coli and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Site-selective glycosylation of proteins: creating synthetic glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

An engineered eukaryotic protein glycosylation pathway in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Yeast expression platforms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

New yeast expression platforms based on methylotrophic Hansenula polymorpha and Pichia pastoris and on dimorphic Arxula adeninivorans and Yarrowia lipolytica - a comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Recombinant protein expression in Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Identification of domains in human beta-hexosaminidase that determine substrate specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Engineering yeast for producing human glycoproteins: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production of heterologous proteins in plants: strategies for optimal expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Trafficking of lysosomal enzymes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

The human SUMF1 gene, required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

A general binding mechanism for all human sulfatases by the formylglycine-generating enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Coexpression of formylglycine-generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Adeno-associated virus gene transfer in Morquio A disease - effect of promoters and sulfatase-modifying factor 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme replacement therapy in a murine model of Morquio A syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Low-scale expression and purification of an active putative iduronate 2-sulfate sulfatase-Like enzyme from Escherichia coli K12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Development of a sandwich enzyme linked immunosorbent assay (ELISA) for the quantification of iduronate-2-sulfate sulfatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Effect of culture conditions and signal peptide on production of human recombinant N-acetylgalactosamine-6-sulfate sulfatase in Escherichia coli BL21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

The Structure of Human GALNS Reveals the Molecular Basis for Mucopolysaccharidosis IV A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Posttranslational modification of serine to formylglycine in bacterial sulfatases. Recognition of the modification motif by the iron-sulfur protein AtsB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Towards revealing the structure of bacterial inclusion bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

The metabolism of Tay-Sachs ganglioside: catabolic studies with lysosomal enzymes from normal and Tay-Sachs brain tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

β-N-acetylhexosaminidase: what's in a name…?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Sphingolipid metabolism diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Establishment of immortalized Schwann cells from Sandhoff mice and corrective effect of recombinant human beta-hexosaminidase A on the accumulated GM2 ganglioside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression of human lysosomal beta-hexosaminidase in yeast vacuoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production of human beta-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogataea minuta MNN4 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Pompe disease: from pathophysiology to therapy and back again

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

New insights into therapeutic options for Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression of the human alpha-galactosidase A in Escherichia coli K-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression and glyco-engineering of alpha-galactosidase A in Pichia pastoris for the treatment of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Wolman disease successfully treated by bone marrow transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Therapy for lysosomal acid lipase deficiency: replacing a missing link

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme therapy for lysosomal acid lipase deficiency in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Purification and characterization of recombinant human lysosomal alpha-mannosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Human α-mannosidase produced in transgenic tobacco plants is processed in human α-mannosidosis cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression, purification and preliminary crystallographic analysis of Drosophila melanogaster lysosomal α-mannosidase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Cloning, expression, purification, and characterization of the human broad specificity lysosomal acid alpha-mannosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Gaucher disease and its treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast, Pichia pastoris.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

New strategies for enzyme replacement therapy for lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Isolation and expression in Escherichia coli of a cDNA clone encoding human beta-glucuronidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Metabolic and cellular bases of sphingolipidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Saposins and their interaction with lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Expression, purification, crystallization, and preliminary X-ray analysis of recombinant human saposin B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Analysis of recombinant human saposin A expressed by Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001

Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.001